Company Description
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs.
The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models.
The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
| Country | Belgium |
| Founded | 2017 |
| IPO Date | Feb 6, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Tim Knotnerus |
Contact Details
Address: Posthoflei 1/6 Antwerp, 2600 Belgium | |
| Phone | 32 3 318 91 70 |
| Website | agomab.com |
Stock Details
| Ticker Symbol | AGMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $16.00 |
| CIK Code | 0002020932 |
| CUSIP Number | 00860C102 |
| ISIN Number | US00860C1027 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Tim Knotnerus MSc, Ph.D. | Chief Executive Officer and Executive Director |
| Paolo Michieli Ph.D. | Founder, Senior Advisor and Member of Scientific Advisory Board |
| Pierre Kemula B.Sc. | Chief Financial Officer |
| Sofie Van Gijsel | Vice President of Investor Relations |
| Ellen Lefever | General Counsel |
| Dr. Philippe Wiesel M.D. | Chief Medical Officer |
| Dr. Paul Van Der Horst Ph.D. | Chief Business Officer |
| Dr. Andrea Sáez Borderías Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2026 | 6-K | Report of foreign issuer |
| Apr 23, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Apr 16, 2026 | SCHEDULE 13G | Filing |
| Mar 11, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2026 | SCHEDULE 13G | Filing |
| Mar 5, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | SCHEDULE 13D | Filing |
| Feb 9, 2026 | 6-K | Report of foreign issuer |
| Feb 6, 2026 | 424B4 | Prospectus |
| Feb 5, 2026 | CERT | Certification by an exchange approving securities for listing |